Shaperon

2008

2016

2018

2019

Started NuSepin® Phase I trial for sepsis
Alzheimer’s disease program selected as government-sponsored research project to develop breakthrough therapeutics

2020

Started NuGel® Phase II trial for atopic dermatitis
Completed NuSepin® Phase I trial for sepsis
Started NuSepin® Phase II trial for COVID-19
Nanobody production platform technology selected as government-sponsored research project

2021

MOU signed with Cellbion Co
Won the Grand Prize in the 'First-in-class' category at the Korea Company Grand Awards 2021
Licensing out agreement with Kukjeon pharmaceutical company
Strategic collaboration agreement with Dong-A ST to co-develop multiple novel biologic therapies in cancer and inflammatory diseases
Nanobody co-development agreement with Korea Research Institute of Bioscience and Biotechnology
Completed NuSepin® Phase II trial for COVID-19
Approved by KFDA for Phase I trial of Alzheimer's disease

2022

Approved by KFDA for Phase IIb/III trail of NuSepin® for COVID-19
Won the Grand Prize in the 'First-in-class' category for the 2nd consecutive year at the Korea Company Grand Awards 2022
NuSepin® selected as KDDF (Korea Drug Development Fund)'s new drug development project for COVID-19 treatment
Licensing out agreement with Bridge Biotherapeutics
MOU signed with Dongkook Pharmaceutical
Won the Grand Prize at the Korea Innovation Awards 2022

2023

Won the Grand Prize in the 'First-in-class' category for the 3rd consecutive year at the Korea Company Grand Awards 2023
Won the Grand Prize in the Bio industry at the 6th National Industry Awards 2023

Immunology